Orogen is pioneering a novel drug discovery platform encompassing proprietary on-DNA chemistry capabilities using unique target-specific focused DNA-encoded libraries (FocusDEL™), open-source DEL, and bespoke chemical synthesis alongside AI-enablement in virtual screening, machine-assisted computation and structural biology/SAR to derive novel chemical matter for medically-important and commercially significant targets. Our primary focus is on immuno-inflammatory diseases where we have identified novel oral inhibitors for a range of cytokine targets, including IL-17, TL1A, TNFa and others. Our lead IL-17 assets exhibit best-in-class properties in in vitro cellular potency, selectivity, permeability and efflux, and in vivo oral bioavailability, half-life, Cmax, clearance, exposure, and IC50/90. We expect near-term development candidate selection to support clinical trials in 2027. We anticipate a second INI development candidate to be selected in 2026.